Royal Bank Of Canada Angion Biomedica Corp. Transaction History

Royal Bank Of Canada

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.94 - $1.23 $277 - $362	295 Added 180.98%	458 $0
Q2 2022 Aug 15, 2022	SELL	$1.1 - $2.23 $1,291 - $2,618	-1,174 Reduced 87.81%	163 $0
Q1 2022 May 16, 2022	SELL	$1.72 - $2.96 $6,995 - $12,038	-4,067 Reduced 75.26%	1,337 $3,000
Q4 2021 Feb 14, 2022	BUY	$2.35 - $9.95 $6,382 - $27,024	2,716 Added 101.04%	5,404 $15,000
Q3 2021 Nov 15, 2021	BUY	$9.31 - $13.25 $21,329 - $30,355	2,291 Added 577.08%	2,688 $26,000

Q2 2021 Aug 16, 2021	BUY	$13.02 - $17.83 $5,168 - $7,078	397 New	397 $5,000

Ticker ANGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,113,300
Description
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primaril...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.